Skip to content

Study · Not a test of the peptide alone · 1999

4 results

Antiproliferative and GH-inhibitory activity of chimeric peptides consisting of GHRP-6 and somatostatin.

Dasgupta P, Singh AT, Mukherjee R

Biochemical and biophysical research communications1 Jun 1999Cited by 7 (Europe PMC)

PMID10362518 (opens in a new tab)DOI10.1006/bbrc.1999.0773 (opens in a new tab)PepBankPUB-10362518
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 01LabNot a test of GHRP-6 aloneIn vitro (cells)Activity measurement

    In GH3 cells, the GHRP‑6–somatostatin chimera GSD had greater antineoplastic activity than RC-160.

    In plain wordsIn lab tests, the GHRP‑6–somatostatin chimera GSD had more antineoplastic activity than RC-160.

    Peptide
    GHRP-6
    Outcome
    IncreaseAntineoplastic activity
    Study

    ratn: not reported in source

    GH3 pituitary adenoma cells
    Comparator
    RC-160
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    One of the chimeric peptides, GSD, exhibited significantly greater (p < 0.001) anti-neoplastic and GH-inhibitory activity, as compared to RC-160.
    2 context sentences
    Summary · context
    Chimeric peptides consisting of growth hormone releasing peptide (GHRP-6) linked to somatostatin (6-11) via an amide bond to provide the effector parts of both the peptides were synthesized.
    Summary · context
    The anti-proliferative, cytotoxic, and GH-inhibitory activities of these chimeric peptides were determined in vitro in the rat pituitary adenoma cell line GH3.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 02LabNot a test of GHRP-6 aloneIn vitro (cells)Activity measurement

    In GH3 cells, the GHRP‑6–somatostatin chimera GSD had greater GH-inhibitory activity than RC-160.

    In plain wordsIn lab tests, the GHRP‑6–somatostatin chimera GSD inhibited growth hormone more than RC-160.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH inhibition
    Study

    ratn: not reported in source

    GH3 pituitary adenoma cells
    Comparator
    RC-160
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    One of the chimeric peptides, GSD, exhibited significantly greater (p < 0.001) anti-neoplastic and GH-inhibitory activity, as compared to RC-160.
    2 context sentences
    Summary · context
    Chimeric peptides consisting of growth hormone releasing peptide (GHRP-6) linked to somatostatin (6-11) via an amide bond to provide the effector parts of both the peptides were synthesized.
    Summary · context
    The anti-proliferative, cytotoxic, and GH-inhibitory activities of these chimeric peptides were determined in vitro in the rat pituitary adenoma cell line GH3.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  3. 03LabNot a test of GHRP-6 aloneIn vitro (cells)Activity measurement

    In GH3 cells, GHRP‑6–somatostatin hybrid peptides showed high affinity for somatostatin receptors.

    In plain wordsIn lab tests, GHRP‑6–somatostatin hybrid peptides bound strongly to somatostatin receptors on GH3 cells.

    Peptide
    GHRP-6
    Outcome
    Not applicableSomatostatin receptor affinity
    Study

    ratn: not reported in source

    GH3 pituitary adenoma cells
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    The hybrid peptides displayed high affinity binding to somatostatin receptors on GH3 cells.
    2 context sentences
    Summary · context
    Chimeric peptides consisting of growth hormone releasing peptide (GHRP-6) linked to somatostatin (6-11) via an amide bond to provide the effector parts of both the peptides were synthesized.
    Summary · context
    The anti-proliferative, cytotoxic, and GH-inhibitory activities of these chimeric peptides were determined in vitro in the rat pituitary adenoma cell line GH3.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  4. 04LabNot a test of GHRP-6 aloneIn vitro (cells)Mechanism

    In GH3 cells, GSD bioactivity involved tyrosine phosphatase stimulation through a cGMP-dependent pathway and pertussis toxin-sensitive G-proteins.

    In plain wordsIn lab tests, GSD activity involved tyrosine phosphatase stimulation through a cGMP-dependent pathway and pertussis toxin-sensitive G-proteins.

    Peptide
    GHRP-6
    Outcome
    IncreaseTyrosine phosphatase signaling
    Study

    ratn: not reported in source

    GH3 pituitary adenoma cells
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones

    Source sentences

    Summary
    The bioactivity of GSD was found to be mediated by the stimulation of tyrosine phosphatase, involving a cGMP-dependent pathway, through pertussis toxin-sensitive G-proteins.
    2 context sentences
    Summary · context
    Chimeric peptides consisting of growth hormone releasing peptide (GHRP-6) linked to somatostatin (6-11) via an amide bond to provide the effector parts of both the peptides were synthesized.
    Summary · context
    The anti-proliferative, cytotoxic, and GH-inhibitory activities of these chimeric peptides were determined in vitro in the rat pituitary adenoma cell line GH3.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.